WO2017203436A3 - Hanta virus gc fragments inhibiting the fusion of the virus with a cell - Google Patents

Hanta virus gc fragments inhibiting the fusion of the virus with a cell Download PDF

Info

Publication number
WO2017203436A3
WO2017203436A3 PCT/IB2017/053045 IB2017053045W WO2017203436A3 WO 2017203436 A3 WO2017203436 A3 WO 2017203436A3 IB 2017053045 W IB2017053045 W IB 2017053045W WO 2017203436 A3 WO2017203436 A3 WO 2017203436A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
fusion
inhibiting
cell
hantavirus
Prior art date
Application number
PCT/IB2017/053045
Other languages
French (fr)
Other versions
WO2017203436A2 (en
Inventor
Nicole TISCHLER
Gonzalo Andrés BARRIGA PINTO
Original Assignee
Fundación Ciencia Para La Vida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundación Ciencia Para La Vida filed Critical Fundación Ciencia Para La Vida
Publication of WO2017203436A2 publication Critical patent/WO2017203436A2/en
Publication of WO2017203436A3 publication Critical patent/WO2017203436A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12111—Hantavirus, e.g. Hantaan virus
    • C12N2760/12133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Abstract

A fragment of the Gc fusion protein of the Hantavirus genus that inhibits the fusion of said virus with a eukaryotic cell, consisting of the partial sequence of the putative Gc domain III, or the putative Gc stem region. A pharmaceutical composition comprising said fragment, useful for preventing, treating and/or inhibiting hantavirus infection of a eukaryotic organism that needs it. Therapeutic methods that comprise the administration of said fragments or said pharmaceutical composition for preventing, treating and/or inhibiting hantavirus infection of a eukaryotic organism. Method of preparing the Gc fusion protein fragment of the Hantavirus genus.
PCT/IB2017/053045 2016-05-23 2017-05-23 Hanta virus gc fragments inhibiting the fusion of the virus with a cell WO2017203436A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2016001238A CL2016001238A1 (en) 2016-05-23 2016-05-23 Fragment of the gc protein of the genus hantavirus that inhibits the fusion of said virus with a eukaryotic cell, which consists of the putative partial iii domain of gc, or the putative partial trunk region of gc; pharmaceutical composition comprising the fragment; and use of said fragment.
CL01238-2016 2016-05-23

Publications (2)

Publication Number Publication Date
WO2017203436A2 WO2017203436A2 (en) 2017-11-30
WO2017203436A3 true WO2017203436A3 (en) 2018-02-01

Family

ID=60411710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053045 WO2017203436A2 (en) 2016-05-23 2017-05-23 Hanta virus gc fragments inhibiting the fusion of the virus with a cell

Country Status (2)

Country Link
CL (1) CL2016001238A1 (en)
WO (1) WO2017203436A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2020002568A1 (en) * 2020-10-05 2022-08-05 Univ Pontificia Catolica Chile Immunogenic formulation containing a modified bcg strain that expresses an andesvirus (andv) protein useful for preventing and treating hanta-andv virus infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298423A (en) * 1987-11-25 1994-03-29 The United States Of America As Represented By The Secretary Of The Army Nucleotide sequences encoding the expression of a Hantaan virus nucleocapsid protein and G1 and G2 glycoproteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298423A (en) * 1987-11-25 1994-03-29 The United States Of America As Represented By The Secretary Of The Army Nucleotide sequences encoding the expression of a Hantaan virus nucleocapsid protein and G1 and G2 glycoproteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CIFUENTES-MUNOZ ET AL.: "Hantavirus Gn and Gc Envelope Glycoproteins: Key Structural Units for Virus Cell Entry and Virus Assembly", VIRUSES, vol. 6, no. 4, 2014, pages 1801 - 1822, XP055461577 *
HALL ET AL.: "Phage display selection of cyclic peptides that inhibit Andes virus infection", J VIROL., vol. 83, no. 17, 2009, pages 8965 - 8969, XP055461574 *
KOCH ET AL.: "Human recombinant neutralizing antibodies against hantaan virus G2 protein", VIROLOGY, vol. 308, no. 1, 30 March 2003 (2003-03-30), pages 64 - 73, XP009052151 *
ZHENG ET AL.: "Defining the Fusion Peptide on the Glycoprotein of Hantavirus GM04-38 Strain", CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY, vol. 29, 2009, pages 706 - 711 *
ZHENG ET AL.: "Defining the N-linked glycosylation site of Hantaan virus envelope glycoproteins essential for cell fusion", J MICROBIOL., vol. 45, no. 1, 2007, pages 41 - 47, XP055461561 *

Also Published As

Publication number Publication date
WO2017203436A2 (en) 2017-11-30
CL2016001238A1 (en) 2018-01-19

Similar Documents

Publication Publication Date Title
EP3795676A4 (en) Application of b. fragilis or akkermansia muciniphila in preparation of drug for preventing or treating tumor
WO2016170348A8 (en) Sarna compositions and methods of use
BR112018003985A2 (en) peptidomimetic macrocycles and their uses
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2015109340A3 (en) Vista antagonist and methods of use
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
WO2017041001A3 (en) Insulin immunoglobulin fusion proteins
MX2021010041A (en) Pharmaceutical compositions comprising akt protein kinase inhibitors.
EP3639829A4 (en) Use of isovalerylspiramycin i, ii and/or iii in preparation of drug for treating and/or preventing tumour, and drug
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
PH12021550122A1 (en) Solubilized apyrases, methods and use
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2022005388A (en) Pyrrolidine and piperidine compounds.
MX2022001261A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.
WO2017203436A3 (en) Hanta virus gc fragments inhibiting the fusion of the virus with a cell
MA40805A (en) LONG-ACTION PHARMACEUTICAL COMPOSITIONS AGAINST HEPATITIS C
EP3677267A4 (en) Pharmaceutical composition for tumor treatment or prevention, method, and use thereof
WO2015171924A3 (en) Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
MX2022001266A (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17802288

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17802288

Country of ref document: EP

Kind code of ref document: A2